215 related articles for article (PubMed ID: 23902803)
1. Peripherally restricted CB1 receptor blockers.
Chorvat RJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4751-60. PubMed ID: 23902803
[TBL] [Abstract][Full Text] [Related]
2. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
3. Pyrazole antagonists of the CB1 receptor with reduced brain penetration.
Fulp A; Zhang Y; Bortoff K; Seltzman H; Snyder R; Wiethe R; Amato G; Maitra R
Bioorg Med Chem; 2016 Mar; 24(5):1063-70. PubMed ID: 26827137
[TBL] [Abstract][Full Text] [Related]
4. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
[TBL] [Abstract][Full Text] [Related]
6. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
7. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
Cluny NL; Vemuri VK; Chambers AP; Limebeer CL; Bedard H; Wood JT; Lutz B; Zimmer A; Parker LA; Makriyannis A; Sharkey KA
Br J Pharmacol; 2010 Oct; 161(3):629-42. PubMed ID: 20880401
[TBL] [Abstract][Full Text] [Related]
8. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
10. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
11. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
12. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Doggrell SA
Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065
[No Abstract] [Full Text] [Related]
13. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Gelfand EV; Cannon CP
Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
[TBL] [Abstract][Full Text] [Related]
14. Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism.
González-Mariscal I; Krzysik-Walker SM; Doyle ME; Liu QR; Cimbro R; Santa-Cruz Calvo S; Ghosh S; Cieśla Ł; Moaddel R; Carlson OD; Witek RP; O'Connell JF; Egan JM
Sci Rep; 2016 Sep; 6():33302. PubMed ID: 27641999
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
[TBL] [Abstract][Full Text] [Related]
16. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Lu D; Dopart R; Kendall DA
Cell Stress Chaperones; 2016 Jan; 21(1):1-7. PubMed ID: 26498013
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
Fulp A; Bortoff K; Seltzman H; Zhang Y; Mathews J; Snyder R; Fennell T; Maitra R
J Med Chem; 2012 Mar; 55(6):2820-34. PubMed ID: 22372835
[TBL] [Abstract][Full Text] [Related]
18. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.
Chorvat RJ; Berbaum J; Seriacki K; McElroy JF
Bioorg Med Chem Lett; 2012 Oct; 22(19):6173-80. PubMed ID: 22959249
[TBL] [Abstract][Full Text] [Related]
19. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
